Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer

Abstract excerpt

The progression of prostate cancer (PCa) to castration-resistant PCa (CRPC) despite continuous androgen deprivation therapy is a major clinical challenge. Over 90% of patients with CRPC exhibit sustained androgen receptor (AR) signaling. KDM4B that removes the repressive mark H3K9me3/2 is a transcriptional activator of AR and has been implicated in the development of CRPC. However, the mechanisms of KDM4B...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Prostate Cancer Treatment and Research
• Share to Protein Degradation and Inhibitors
• Share to Ubiquitin and proteasome pathways